Clinical Trials Logo

Lymphoma, Non-Hodgkin clinical trials

View clinical trials related to Lymphoma, Non-Hodgkin.

Filter by:

NCT ID: NCT05798897 Recruiting - Hodgkin Lymphoma Clinical Trials

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

APOLLO
Start date: January 2, 2023
Phase: Phase 1
Study type: Interventional

This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10^6 cells (flat dosing).

NCT ID: NCT05794958 Recruiting - Clinical trials for Non-Hodgkin Lymphoma

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Start date: May 23, 2023
Phase: Phase 1
Study type: Interventional

This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.

NCT ID: NCT05784441 Recruiting - Clinical trials for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Start date: November 6, 2023
Phase: Phase 1
Study type: Interventional

The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: - can a safe dose of JNJ-90009530 be determined that is safe and well tolerated by patients. - will JNJ-90009530 help patients achieve a response and for how long?

NCT ID: NCT05783609 Recruiting - Follicular Lymphoma Clinical Trials

Epcoritamab and Rituximab for First-line Follicular Lymphoma

Start date: June 21, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: - Rituximab (a type of monoclonal antibody therapy) - Epcoritamab (a T-cell bispecific antibody)

NCT ID: NCT05783596 Recruiting - Follicular Lymphoma Clinical Trials

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Start date: July 18, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: - Glofitamab (a type of immunotherapy) - Obinutuzumab (a type of immunotherapy)

NCT ID: NCT05768529 Recruiting - Clinical trials for Relapsed or Refractory Non-Hodgkin's Lymphoma

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: March 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a Phase I/II, single-arm, open-label clinical trial, and its primary objective of phase I and phase II is to evaluate the safety and efficacy of U16 Injection in the treatment of relapsed or refractory NHL,respectively.

NCT ID: NCT05745181 Recruiting - Clinical trials for Acute T-lymphoblastic Lymphoma

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of anti-CD1a CAR-T in the treatment of relapsed refractory acute T-lymphoblastic leukemia/lymphoblastic lymphoma.

NCT ID: NCT05741359 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Start date: April 25, 2023
Phase: Phase 1
Study type: Interventional

This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.

NCT ID: NCT05721222 Recruiting - Clinical trials for Renal Cell Carcinoma

PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)

Start date: March 15, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1160 in participants with solid tumors. Participants will have solid tumor or liquid cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This Phase 1/2 study will have two parts. Part A of the study will find out how much and how frequently PRO1160 should be given to participants. Part B will use the dose and schedule found in Part A to find out how safe PRO1160 is and if it works to treat the diseases under study. The diseases under study will be Renal Cell Carcinoma (RCC),Nasopharyngeal Carcinoma (NPC) and Non-Hodgkin Lymphoma (NHL).

NCT ID: NCT05702853 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Start date: November 6, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).